Key Details
Price
$2.50Annual ROE
50.34%Beta
0.89Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi's Board of Directors, serving on Metagenomi's Audit and Compensation committees, effective January 27, 2025.
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113560&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113547&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK , Nov. 25, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113528&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113509&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESSWIRE / November 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about February 9, 2024, are encouraged to contact the firm before November 25, 2024.
NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company's initial public offering conducted between February 9 and 13, 2024 (the “IPO”), of the important November 25, 2024 lead plaintiff deadline.
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113468&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 24, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113336&wire=1 or contact Joseph E. Levi, Esq.
FAQ
- What is the ticker symbol for Metagenomi?
- Does Metagenomi pay dividends?
- What sector is Metagenomi in?
- What industry is Metagenomi in?
- What country is Metagenomi based in?
- When did Metagenomi go public?
- Is Metagenomi in the S&P 500?
- Is Metagenomi in the NASDAQ 100?
- Is Metagenomi in the Dow Jones?
- When was Metagenomi's last earnings report?
- When does Metagenomi report earnings?
- Should I buy Metagenomi stock now?